Lucentis (ranibizumab) / Roche, Novartis, Santen, China Medical System - LARVOL DELTA

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema (clinicaltrials.gov) - P3 | N=70 | Completed | Sponsor: Incepta Pharmaceuticals Ltd | Recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ May 2026 | Trial primary completion date: Oct 2025 ➔ Mar 2026

Trial completion • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Diabetic Macular Edema • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders

Pharmacodynamics of Free VEGF After Treatment with the Port Delivery Platform with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration. (PubMed, Ophthalmol Sci) - P2, P3 | "These findings demonstrate that PDS 100 mg/mL Q24W suppresses AH free VEGF throughout the entire 24-week refill-exchange interval and to an extent similar to that at 4 weeks after intravitreal ranibizumab. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."

Journal • PK/PD data • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Fédération France Macula Practical Guidelines for the Use of Anti-VEGF Biosimilars (PubMed, J Fr Ophtalmol) - "Anti-VEGF biosimilars are expected to play an increasingly important role in retinal care by expanding treatment accessibility and contributing to healthcare sustainability. Their successful implementation requires a thorough understanding of regulatory requirements, careful patient selection, and continued post-marketing surveillance. These recommendations provide a practical framework for the integration of biosimilars into contemporary retinal practice."

Clinical guideline • Journal • Ophthalmology • Retinal Disorders

Airway management and postoperative respiratory recovery after intravitreal injection in preterm infants. (PubMed, Pediatr Res) - "In preterm infants undergoing intravitreal injection under general anesthesia in the operating room, laryngeal mask airway use was associated with a lower risk of respiratory support escalation within 24 hours than endotracheal intubation. Using inverse probability of treatment weighting to address measured baseline differences, this study provides a confounding-adjusted estimate and extends observations from laser photocoagulation to the briefer setting of intravitreal injection. The findings are associative and hypothesis-generating and may inform airway-device selection when laryngeal mask placement is technically feasible and clinically considered an appropriate airway option. Prospective multicenter studies are warranted."

Journal • Anesthesia • Retinal Disorders • Retinopathy of Prematurity

Retinopathy of Prematurity in the Anti-VEGF Era: Screening Systems and Practical Treatment Decision-Making Across Anti-VEGF, Laser, and Surgery. (PubMed, Prog Retin Eye Res) - "Ranibizumab and aflibercept appear to have more reassuring systemic profiles than bevacizumab, although long-term comparative data remain limited. Faricimab and topical dexamethasone remain investigational. Future priorities include integrated screening networks, standardized retreatment algorithms, and longitudinal registries tracking ocular and developmental outcomes."

Journal • Review • Ophthalmology • Retinal Disorders • Retinopathy of Prematurity

Differential Remodeling of the Macular Neovascular Network under Different Anti-VEGF Agents in Age-Related Macular Degeneration. (PubMed, Ophthalmol Sci) - "A total of 120 eyes from 102 patients with nAMD treated with ranibizumab 0.5 mg every 4 weeks (n = 30), aflibercept 2.0 mg every 4 weeks (n = 30), aflibercept 8.0 mg every 12 weeks (n = 30), or faricimab 6.0 mg every 8 weeks (n = 30) in a treat-and-extend regimen. Long-term studies are needed to determine whether deeper anatomical suppression translates into improved clinical outcomes or influences the trajectory of macular atrophy. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Comparative Histopathological Effects of Intra-Articular Bevacizumab, Ranibizumab, and Aflibercept in Experimental Osteoarthritis. (PubMed, J Clin Med) - "Although no treatment significantly improved histopathological outcomes compared with the control group after adjustment for multiple comparisons, ranibizumab showed lower OARSI stage and total scores than aflibercept. These findings indicate that the evaluated anti-VEGF agents may not exert equivalent biological effects and warrant further investigation in adequately powered experimental studies."

Journal • Anesthesia • Immunology • Osteoarthritis • Pain • Rheumatology

Adoption patterns of anti-vascular endothelial growth factor therapies in retinal disease. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "Real-world adoption of anti-VEGF therapies differs markedly across retinal diseases and agents. Aflibercept demonstrated sustained long-term use, while faricimab showed rapid early uptake. Changes in agent-specific utilization occurred alongside substantial growth in the absolute number of treated patients over the study period, underscoring the importance of interpreting drug-specific trajectories in the context of overall treatment activity."

Journal • Age-related Macular Degeneration • Cardiovascular • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Understanding anti-vascular endothelial growth factor medications: chemical properties, costs, and side effects. (PubMed, J Med Life) - "This narrative review addressed the fact that the pharmacological properties, safety profiles, and cost-effectiveness of the currently marketed anti-VEGF intravitreal agents (i.e. bevacizumab, ranibizumab, aflibercept, brolucizumab, pegaptanib, and recently faricimab) differ and therefore, each of these agents, have their own unique molecular structure, target specificity, duration of action in the eye, and systemic circulation, each of which will affect the dosing intervals and treatment burden as well as the safety and adverse events associated with each drug. While anti-VEGF therapies are highly effective, the outcomes regarding safety, efficacy, and cost depend heavily on the study design and reflect the actual treatment paradigm and continuum of care within the healthcare system. The various attributes of agents should help personalize a patient's treatment approach while also addressing potential challenges related to the safety, efficacy, and longevity of..."

Adverse events • Journal • Review • Age-related Macular Degeneration • Diabetic Macular Edema • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Congestive heart failure and other cardiac adverse events after intravitreal anti-VEGF therapy: a systematic review and meta-analysis. (PubMed, Can J Ophthalmol) - "CHF and other AEs after intravitreal anti-VEGF therapy were uncommon in RCTs and comparable across agents. The aflibercept-sham CHF signal was based on limited evidence and should be interpreted cautiously."

Adverse events • Journal • Retrospective data • Age-related Macular Degeneration • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetic Macular Edema • Heart Failure • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Safety of intravitreally applied epidermal growth factor receptor antibody panitumumab. (PubMed, Acta Ophthalmol) - "Repeated intravitreal panitumumab applications in various doses, single or combined with ranibizumab, were not associated with severe ocular or systemic side effects."

Journal • Age-related Macular Degeneration • Fibrosis • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • EGFR

PRP VS PRP&RZB: Laser Photocoagulation and Ranibizumab Treatment in Proliferative Diabetic Retinopathy (clinicaltrials.gov) - P=N/A | N=80 | Completed | Sponsor: Aswan University

New trial • Diabetic Retinopathy • Retinal Disorders

Molecular Determinants of Intravitreal Anti-VEGF Durability: Drug Architecture, Intraocular Pharmacokinetics, Target Biology and Treatment Resistance. (PubMed, Int J Mol Sci) - "Trial evidence for ranibizumab, aflibercept, conbercept, brolucizumab and faricimab shows that extended dosing can arise from greater starting exposure, altered binding architecture or pathway expansion without a proportionate change in intrinsic ocular half-life. We propose that durability be defined as a time-to-threshold phenotype integrating active target-site exposure, biological demand, anatomical recurrence, all treatment-related procedures and safety. Standardised estimands, longitudinal human ocular sampling, spatial exposure methods and externally validated mechanism-informed models are needed to make molecular durability comparable and clinically actionable."

Journal • PK/PD data • Review • Age-related Macular Degeneration • Cardiovascular • Diabetic Macular Edema • Gene Therapies • Macular Degeneration • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

BURGUNDY: Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=177 | Completed | Sponsor: Hoffmann-La Roche | Active, not recruiting ➔ Completed

First-in-human • Trial completion • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

SAHARA: Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05) (clinicaltrials.gov) - P3 | N=400 | Not yet recruiting | Sponsor: Ollin Biosciences, Inc.

New P3 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Faricimab in previously treated nAMD: Real-World Outcomes of a No-Loading-Dose Switching Protocol. (PubMed, Ophthalmologica) - "In previously treated nAMD patients, switching to faricimab without a loading dose achieved meaningful treatment interval extension, potentially reducing treatment burden without compromising efficacy."

Journal • Real-world evidence • Age-related Macular Degeneration • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis • Wet Age-related Macular Degeneration

Renal Safety of Intravitreal Ranibizumab and the Effects of SGLT2 Inhibition in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial. (PubMed, Diabetes Obes Metab) - "No statistically significant exposure-response association was detected between cumulative IVR and renal markers within the COMET trial cohort and dosing range. Because all participants received IVR and the sample size was modest, small cumulative renal effects cannot be excluded."

Journal • Retrospective data • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Hematological Disorders • Macular Edema • Metabolic Disorders • Ophthalmology • Renal Disease • Retinal Disorders • Type 2 Diabetes Mellitus

Novartis India Limited has announced the signing of an exclusive promotion and distribution agreement with Novartis Healthcare Private Limited (NHPL) on September 8, 2026. (Indian Pharma Post) - "This strategic collaboration marks the company's entry into the ophthalmology therapy segment and serves to expand its overall commercial portfolio in the country...Under the terms of the agreement, Novartis India Limited has acquired the exclusive rights to promote and distribute NHPL's retina portfolio across India. The portfolio includes key products Accentrix (ranibizumab) and Pagenax (brolucizumab). In exchange for these exclusive rights, the company will pay an upfront consideration of Rs. 10 crores to NHPL."

Licensing / partnership • Diabetic Macular Edema • Diabetic Retinopathy • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

SSGJ-601 versus Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion: 52-Week Results from a Phase 3 Study. (PubMed, Ophthalmol Retina) - "This study supports the conclusion of no clinical meaningful differences in efficacy, safety, and immunogenicity between SSGJ-601 and ranibizumab in patients with macular edema secondary to BRVO. Additionally, treatment transitioned to a pro re nata (PRN) schedule based on investigator-assessed retreatment criteria resulted in sustained benefits in visual and anatomical outcomes."

Journal • P3 data • Diabetic Retinopathy • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Stereospecific Peptide-Polysaccharide Conjugates Enable Noninvasive Therapy of Neovascular Age-Related Macular Degeneration. (PubMed, J Am Chem Soc) - "Following topical administration, D-PPC efficiently overcame ocular barriers and penetrated choroidal lesions while markedly suppressing pathological angiogenesis in a laser-induced choroidal neovascularization mouse model, comparable to that of intravitreal ranibizumab...Notably, D-PPC exhibited no detectable ocular or systemic toxicity. This study establishes chirality-engineered peptide-polysaccharide conjugates as a noninvasive and effective therapeutic for posterior ocular diseases, providing a structural and mechanistic blueprint for future translational ophthalmic applications."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Nano-drops of biomimetic macromolecular drugs based on macrophage membranes for targeted treatment of fundus diseases. (PubMed, Mater Today Bio) - "Although multiple dosing was required to achieve therapeutic efficacy comparable to that of a single intravitreal ranibizumab injection, M@R exhibited markedly improved safety profiles, with no observable local ocular toxicity or systemic adverse effects following repeated administration. Collectively, these findings establish macrophage membrane-coated nanovesicles as a promising platform for barrier-penetrating, inflammation-targeted delivery of biologics in the treatment of fundus diseases."

Journal • Age-related Macular Degeneration • Diabetic Retinopathy • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders

Comparison of adverse events of three anti-VEGF drugs for the treatment of age-related macular degeneration. (PubMed, Malays J Pathol) - "The neovascular form of AMD is currently treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents, particularly ranibizumab, aflibercept, and bevacizumab. Current evidence suggests an overall comparable efficacy and safety profile among the three agents, although Bevacizumab requires stricter preparation and monitoring protocols because of its off-label use. Pharmacovigilance remains essential for identifying safety signals, supporting regulatory decisions, and optimising therapeutic strategies in ophthalmology."

Adverse events • Clinical • Journal • Review • Age-related Macular Degeneration • Cardiovascular • Macular Degeneration • Ophthalmology • Retinal Disorders

Optical Coherence Tomography Biomarkers in Diabetic Macular Edema and Their Role in Predicting Visual Outcome After Ranibizumab or Triamcinolone Injection. (PubMed, Cureus) - "Also, a significant correlation was noted between BCVA and CMT (r=-0.455; p<0.001), SRF height (r=-0.438; p=0.001), and intraretinal cyst height (r=-0.540; p<0.001). Conclusion OCT biomarkers can be used to monitor therapeutic response and to predict visual outcome after intravitreal injection in DME. The presence of more HRF at baseline might be considered for steroid injection."

Biomarker • Journal • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Aggressive retinopathy of prematurity: characteristics and risk factors for retreatment. (PubMed, Br J Ophthalmol) - "A-ROP is associated with lower BW, lower GA at birth and more posterior ROP zone than non-A-ROP. Lower BW and initial ranibizumab treatment are related to greater risk of repeat anti-VEGF injection. There was more retreatment in zone II A-ROP eyes compared with those in zone I, which did not persist after correction for bilaterality."

Journal • Retinal Disorders • Retinopathy of Prematurity

Differential efficacy of Conbercept vs. Ranibizumab on retinal microstructural changes in macular edema secondary to retinal vein occlusion during the loading phase. (PubMed, Front Med (Lausanne)) - "Conbercept and Ranibizumab showed comparable primary outcomes and subtle divergences in exploratory secondary OCT biomarkers during the loading phase: Conbercept yielded greater DRIL reduction, whereas Ranibizumab achieved lower CMT and IRF at early time points. These preliminary findings may generate hypotheses for an OCT phenotype-driven approach to precision anti-VEGF therapy in RVO-ME."

Journal • Macular Edema • Ophthalmology • Retinal Vein Occlusion